D
eep vein thrombosis (DVT) has an annual incidence of approximately 1 in 500, 1 and approximately 1 in 3 DVT patients develop post-thrombotic syndrome, 2 which is characterized by leg pain, swelling, and ulceration.
Venous thrombus resolution is a slow, natural process. 3 Veins that recanalize more rapidly following a DVT have preserved valve integrity and a lower incidence of venous obstruction, which is associated with improved clinical outcome. 4 -6 Anticoagulation is the usual treatment for DVT, but this does not promote resolution and carries a risk of major bleeding. Thrombolysis and thrombectomy remove thrombus rapidly but may be contraindicated in many patients and carry the risks of major bleeding or rethrombosis.
The organization of venous thrombi involves several processes, including recruitment of inflammatory cells, myofibroblasts, and endothelial cells, leading to the formation of neovascular channels both throughout and around the thrombus. [7] [8] [9] Potent angiogenic and chemotactic factors are expressed within the thrombus during natural resolution, 10 -12 and increasing their levels in the thrombus enhances its resolution. [12] [13] [14] [15] The stimulus for the production of these factors remains unknown.
Hypoxia is characteristic of several pathophysiological states, including cancer, atherosclerosis, chronic obstructive pulmonary disease, pre-eclampsia, and cardiovascular ischemic disorders. 16 Low oxygen tension stimulates the transcription of a number of genes, including those encoding vascular endothelial growth factor (VEGF), which is a potent promoter of both physiological and pathological vascular remodeling. 17, 18 Under hypoxic conditions, VEGF stimulates elongation and branching of endothelial cells, 19 mobilizes progenitor cells from the bone marrow, and is chemotactic for both monocytes and endothelial cells. 20 -22 Increasing the expression of VEGF within the thrombus by directly injecting either VEGF recombinant protein, 14 VEGF naked plasmid, 23 or VEGF adenovirus 24 results in an acceleration in thrombus organization and resolution.
The remodeling response that follows hypoxia is controlled primarily by hypoxia-inducible factor 1 (HIF1). 17 HIF1 is a heterodimeric transcription factor composed of ␣ and ␤ subunits. HIF1␤ is stable and constitutively expressed, but HIF1␣ is regulated in an oxygen-dependent manner through the activity of prolyl hydroxylase domain (PHD) proteins 1, 2, and 3. 25 During hypoxia, HIF1␣ accumulates and translocates to the nucleus, where it forms the active HIF1 complex with HIF1␤. 26 HIF1 binds to the hypoxia-responsive element of target genes such as VEGF and upregulates their transcription. 18 L-Mimosine is an effective PHD inhibitor that binds to the active site of PHDs and therefore interferes with the reconstitution of the active enzyme. 27 It is structurally related to 2-oxoglutarate (a PHD substrate) and probably competes with 2-oxoglutarate at the catalytic core of PHDs. 28 L-Mimosine has been used to increase the levels of HIF1␣ and induce angiogenesis both in vitro 29 and in vivo. 28 -30 The recruitment of monocytes and endothelial cells, which infiltrate resolving thrombus, is also associated with hypoxia. 31 Stimulating or inhibiting macrophage recruitment has profound effects on thrombus recanalization and resolution. 13, 24, 32, 33 We hypothesized that the formation of an occlusive thrombus causes relative hypoxia of the cells within it and that this is a stimulus for the expression of angiogenic factors that promote thrombus recanalization and resolution, possibly through the stimulation of monocyte recruitment.
The aims of this study were to determine whether hypoxia and HIF1␣ are induced in the resolving thrombus and whether this leads to an increase in the production of angiogenic growth factors such as VEGF. A second aim was to determine whether administration of the PHD inhibitor L-mimosine increases HIF1␣ expression in the thrombus and augments its recanalization and resolution.
Methods

Mouse Model of Venous Thrombosis
Experimental venous thrombi were induced in the inferior vena cava (IVC) of 8-week-old male BALB/c mice using a combination of blood flow restriction and endothelial disturbance as previously described. 7, 33, 34 In this model, totally occlusive thrombi form within 4 hours following thrombus induction and resolve completely by day 21. 33, 34 
Assessment of Hypoxia in Thrombus During Natural Resolution
An oxygen microelectrode and tissue-monitoring system (OxyLab, Oxford Optronix) was used to measure oxygen tension (pO 2 ) in the thrombus. The microelectrode was inserted through the vein wall into the thrombus at 1 day (nϭ13), 3 days (nϭ10), 7 days (nϭ13), and 14 days (nϭ10) after induction. Normal venous pO 2 was measured by inserting the microelectrode into the blood of the right ventricle (nϭ16). Thrombus was removed from the vein, snap frozen, and stored at Ϫ80°C until measurement of HIF1␣ and VEGF expression by enzyme-linked immunosorbent assay (ELISA).
HIF1␣ and VEGF Expression in Thrombus During Natural Resolution
As HIF1␤ is constitutively expressed, the rate-limiting factor for HIF1 activation is accumulation and translocation of HIF1␣ to the nucleus. Both the nuclear and cytoplasmic fractions of thrombus homogenates were therefore extracted using an extraction kit according to the manufacturer's instructions (NE-PER Extraction Kit, Pierce). [35] [36] [37] Soluble protein concentrations in each fraction were measured using the Coomassie Plus modified Bradford assay (Pierce).
The levels of HIF1␣ in nuclear fractions were measured using a human/mouse HIF1␣ ELISA (R&D Systems). The level of VEGF in the cytoplasmic fractions was measured using a mouse VEGF 164 ELISA (R&D Systems).
Localization of HIF1␣ by Immunohistochemistry
Contiguous transverse paraffin sections (5 m) of 1-day-old thrombus (nϭ3) were immunostained for HIF1␣ (anti-HIF1␣, Stratech), macrophages (anti-Mac-2, BioLegend), and neutrophils (anti-NIMP R14, Abcam) following antigen retrieval by pressure cooking sections in citrate buffer (0.3% sodium citrate, pH 6). Primary antibody binding was detected using biotinylated rabbit anti-rat (Dako) and ExtrAvidin horseradish peroxidase complex (Sigma). Isotype-matched IgG was used as a negative control. Peroxidase activity was visualized using the Vector SG peroxidase substrate kit (Vector Laboratories), and sections were counterstained using nuclear fast red.
Treatment With L-Mimosine
Dosing Regimen
L-Mimosine dosage is limited by its low solubility. 29 A dosing regimen of 50 mg/kg per day given over a 2-week period upregulates HIF1␣, 30 and our dosing regimen was designed to administer the maximum amount of L-mimosine possible. An initial intraperitoneal injection of 300 mg/kg L-mimosine in 10% NaHCO 3 , pH 7.2 (Sigma), was administered 5 hours after thrombus induction. A subsequent injection of 300 mg/kg was administered 16 hours later. Additional daily injections of 120 mg/kg were administered to animals in which the effect of L-mimosine was to be evaluated over 7 and 10 days.
Effect on Thrombus Formation
Thrombus was formed in 30 mice. Mice were treated with either L-mimosine or a vehicle control (nϭ15 per group) 5 hours later. Thrombi were harvested 24 hours after thrombus induction and weighed.
Effect on HIF1␣ and Angiogenic Factor Production
Thrombus was formed in 30 mice. Mice were treated with either L-mimosine or vehicle control (nϭ15 per group). Thrombi were harvested at day 7, immediately snap frozen, and stored at Ϫ80°C. All thrombi were weighed, and 14 thrombi (nϭ7 per group) underwent nuclear and cytoplasmic extraction. HIF1␣ expression was measured in nuclear fractions, whereas VEGF expression was measured in cytoplasmic fractions.
The remaining 16 thrombi (nϭ8 per group) were analyzed using a protein array (Mouse Angiogenesis Array Kit, R&D Systems) for the expression of 15 factors whose transcription is known to be regulated by HIF1 (ie, angiopoietin 1, 38 endoglin, 39 endothelin 1, 40 insulin-like growth factor binding protein 1, 41 49 [TIMP1], and VEGF 50 ). The mean pixel density of the duplicate spots for each factor was measured using Quantity One (BioRad) and expressed as a percentage of the mean pixel density of the duplicate positive controls on the same membrane. The levels of VEGFR1 were measured using a mouse VEGFR1 ELISA (R&D Systems).
Effect on Thrombus Resolution, Neovascularization, and Vein Recanalization
Thrombus was formed in 26 mice. Mice were treated with either L-mimosine or vehicle control (nϭ13 per group). The IVC containing thrombus was harvested at day 7 (nϭ6 per group) and 10 (nϭ7 per group) and fixed in 10% formalin. Transverse paraffin sections (5 m) were taken at 300-m intervals along the entire length of the thrombus and stained with hematoxylin and eosin. Images of whole tissue sections were obtained in a blinded fashion using Image Pro Plus (Media Cybernetics). Estimates of thrombus volume (mm 3 ) and IVC recanalization (% area of lumen) were obtained as previously described. 24 Sections were also immunostained for CD31 (anti-CD31, Santa Cruz Biotechnology), following antigen retrieval by incubation with Proteinase K. Primary antibody binding was detected using biotinylated rabbit anti-goat (Dako) and ExtrAvidin alkaline phosphatase complex (Sigma). Isotype-matched IgG was used as a negative control. Phosphatase activity was visualized using the Vector BCIP/ NBT substrate kit (Vector Laboratories), and sections were counterstained using nuclear fast red.
An estimate of neovascularization was obtained in a blinded fashion by counting the number of vascular channels within the thrombus (ie, channels that contained erythrocytes or were lined with cells that stained positive for the endothelial cell marker CD31). An average count was taken throughout the length of the thrombus.
Effect on Macrophage and Neutrophil Content
Paraffin sections (5 m) of 7-day-old (nϭ6 per group) and 10-dayold (nϭ7 per group) thrombi and surrounding IVC of mice treated with L-mimosine or vehicle control were immunostained using the mouse macrophage marker Mac-2 (BioLegend) or the mouse neutrophil marker NIMP R14 (Abcam) as previously described. Images were obtained of sections taken at 300-m intervals throughout the length of the thrombus. Macrophage or neutrophil content was estimated in a blinded fashion by measuring the percentage area of each thrombus or vein wall containing Mac-2 or NIMP R14 stain using Image Pro Plus software (Media Cybernetics) as previously described. 24 
Statistical Analysis
One-way analysis of variance with the Bonferroni post hoc test was used to determine whether there was a relationship between pO 2 , HIF1␣, or VEGF in the thrombus and time after thrombus induction. The relationship between pO 2 and HIF1␣ expression was tested using the Spearman correlation (RS), and the relationship between HIF1␣ and VEGF expression was tested using the Pearson correlation (R). To compare differences between L-mimosine-treated mice and controls, statistical significance (PϽ0.05) was determined by using parametric or nonparametric tests as appropriate. Data are expressed as meansϮstandard error.
Results
Oxygen Tension in the Naturally Resolving Thrombus pO 2 in the thrombus at 1 day (8.0Ϯ1.3 mm Hg), 3 days (22.9Ϯ2.7 mm Hg), and 7 days (29.2Ϯ2.5 mm Hg) after thrombus induction was significantly lower than the pO 2 of venous blood (78.0Ϯ0.9 mm Hg, PϽ0.0001 for all 3 comparisons, Figure 1A ). There was an inverse relationship between pO 2 in the thrombus and time following thrombus induction (PϽ0.0001). pO 2 in the thrombus was significantly lower at day 1 compared with days 3 (PϽ0.001) and 7 (PϽ0.001, Figure 1A ). There was no difference in pO 2 in the thrombus between days 3 and 7.
HIF1␣ Expression and Localization in the Thrombus During Natural Resolution
HIF1␣ at day 1 (13.5Ϯ1.7 pg/mg) was significantly higher than at day 3 (4.2Ϯ0.4 pg/mg, PϽ0.001) and day 7 (7.2Ϯ1.1 pg/mg, PϽ0.01, Figure 1B ). There was no difference between HIF1␣ in thrombi at day 3 compared with day 7. There was a strong negative correlation between pO 2 and HIF1␣ expression in the thrombi at days 1, 3, and 7 after thrombus formation (RSϭϪ0.77, nϭ36, PϽ0.0001, Figure 1C ). Thrombus at day 14 was too small to yield a sufficient amount of nuclear extract to allow measurement of HIF1␣ expression by ELISA.
Immunohistochemical analysis showed that at day 1 (the time of greatest hypoxia), HIF1␣ was expressed mainly in cell-dense regions within the thrombus and appeared to be almost completely located within the nuclei of cells having a polymorphonuclear morphology and staining positively for the neutrophil marker NIMP R14 (Figure 2 ). There were very few macrophages present in the thrombus at this time, as shown by the minimal amount of Mac-2 staining (Figure 2 ).
VEGF Expression in the Naturally Resolving Thrombus
VEGF in the thrombus was elevated at 3 days (32.1Ϯ4.1 pg/mg) and 7 days (26.7Ϯ3.0 pg/mg) compared with 1 day (4.4Ϯ0.3 pg/mg) and 14 days (8.5Ϯ0.7 pg/mg) after thrombus induction (PϽ0.001 for all 4 comparisons, Figure 3A ). There was a strong positive relationship between HIF1␣ and VEGF in the thrombus at 3 days (Rϭ0.81, nϭ10, PϽ0.005, Figure 1 . Oxygen tension and HIF1␣ expression in the naturally resolving thrombus. A, pO 2 at day 1 was lower than that at days 3 and 7. pO 2 at days 1, 3, and 7 was lower than pO 2 of venous blood. B, HIF1␣ expression was greater at day 1 than at days 3 and 7. *PϽ0.001 versus day 3 and PϽ0.01 versus day 7; **PϽ0.001 versus days 3 and 7; ***PϽ0.0001 versus days 1, 3, and 7. C, Negative correlation between pO 2 and HIF1␣ expression (RSϭϪ0.77, nϭ36, PϽ0.0001). Figure 3B ) and 7 days (Rϭ0.85, nϭ13, PϽ0.0005, Figure  3C ) after thrombus formation. Figure 5B ). Recanalization of the IVC was increased by 2-fold following L-mimosine treatment compared with control at day 7 (8.3Ϯ1.5% versus 4.2Ϯ1.0%, PϽ0.05) and also at day 10 (20.6Ϯ2.2 versus 9.0Ϯ1.2%, PϽ0.005, Figure 5C ). Thrombus neovascularization was increased by 3-fold in mice treated with L-mimosine (5.8Ϯ0.9 channels) compared with control at day 7 (1.9Ϯ0.3 channels, PϽ0.005) and by 2-fold at day 10 (4.6Ϯ0.3 versus 2.3Ϯ0.2 channels, PϽ0.001, Figure 5D ).
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The Effect of L-
The Effect of L-Mimosine on Macrophage and Neutrophil Content
Thrombus There was no difference in the numbers of macrophages (1.7Ϯ0.1% versus 1.5Ϯ0.3%, PϾ0.1) or neutrophils (1.7Ϯ0.2% versus 1.3Ϯ0.3%, PϾ0.1) in the thrombus of L-mimosine-treated mice compared with vehicle-treated mice at day 7. By day 10, there were greater numbers of both Figure  6A ) and neutrophils (2.0Ϯ0.2 versus 1.0Ϯ0.2%, PϽ0.05, Figure 6B ) in the thrombus of mice treated with L-mimosine compared with vehicle.
Vein Wall
Macrophage content was higher in the vein wall of Lmimosine-treated mice compared with controls at both day 7 (3.7Ϯ0.5 versus 1.4Ϯ0.3%, PϽ0.01) and day 10 (7.5Ϯ0.7 versus 4.7Ϯ0.6%, PϽ0.05, Figure 6C ). Neutrophil content in the IVC of mice treated with L-mimosine was also increased at day 7 (12.0Ϯ0.6 versus 8.1Ϯ0.6%, PϽ0.005) and day 10 (8.2Ϯ0.4 versus 5.7Ϯ0.7%, PϽ0.01, Figure 6D ).
Discussion
This study is the first to show a relative hypoxia within newly formed thrombi, with a pO 2 of approximately 10% of that in circulating venous blood. This is closely related to the presence of increased levels of HIF1␣ and angiogenic factors within the thrombus. Preventing HIF1␣ degradation with the PHD inhibitor L-mimosine led to increased angiogenic factor expression and inflammatory cell content, and it enhanced IVC recanalization and thrombus resolution.
Hypoxia within the thrombus probably results from the formation of an occlusive thrombus, the volume and crosssectional area of which are greatest at day 1 in this model. 32 The radius of the thrombus at this time point exceeds the maximal oxygen diffusion distance of 100 to 250 m. 51 Recanalization and contraction of the thrombus away from the IVC is seen at days 3 and 7. 8, 12 This allows blood flow into and around the thrombus, which, together with the decreased oxygen diffusion distance that results from reduced thrombus size, may be the reason for the rise in pO 2 levels observed at these time points. This would be in keeping with data from tumor models, which shows increased tumor pO 2 as tumor volume decreases. 53 The finding that thrombi at days 3 and 7 remain hypoxic relative to the pO 2 of venous blood could be the result of an increase in oxygen demand in the 
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face of a relatively poor blood supply in these rapidly remodeling structures. There was a strong inverse correlation between HIF1␣ and pO 2 , suggesting that HIF1␣ stabilization is oxygen dependent in the naturally resolving thrombus. HIF1␣ expression may, however, be regulated in an oxygen-independent manner via the phosphatidylinositol 3-kinase and extracellular signalregulated kinase pathways. Growth factors that have been shown to stimulate HIF1␣ production include insulin, interleukin 1␤, 54 and insulin-like growth factors (IGF) 1 and 2. 42, 55 Neutrophils are the predominant nucleated cell-type present in the newly formed and 1-day-old thrombus 32, 56 and are capable of expressing interleukin 1␤. 57 Therefore, we cannot discount the possibility that these pathways may be partly responsible for the HIF1␣ levels found in this study.
HIF1␣ staining in day 1 thrombi was located in the nucleus of neutrophils (NIMP R14 -positive polymorphonucleated cells). Staining for macrophages (Mac-2-positive cells) in contiguous sections revealed very few of these cells were present in the thrombus at this time point. These data were not unexpected, as macrophages infiltrate the thrombus much later, 32 possibly as a result of HIF1-mediated transcriptional upregulation of growth factors such as VEGF, which facilitate chemoattraction of monocytes/macrophages through VEGFR1. 21 We have previously shown that upregulating VEGF within the thrombus enhances its resolution. 14, 23, 24 In this study, there was a strong positive correlation between HIF1␣ and VEGF expression in the thrombus during natural resolution. Upregulation of HIF1␣ is a more efficacious stimulus for angiogenesis than upregulation of VEGF alone. 58 We therefore hypothesized that augmenting the accumulation of HIF1␣ should enhance thrombus resolution by stimulating local angiogenesis through the expression of multiple growth and chemotactic factors 17, 18 and in this way be more effective than upregulating a single factor, such as VEGF. 14, 24 These growth and chemotactic factors could affect thrombus remodeling and subsequent resolution in a number of ways: first, by promoting endothelial cell proliferation and survival 59 and mobilizing vascular progenitors, 59 ,60 which lead to the development of vessels within and around the thrombus. 18 Second, they could work by recruitment and activation of monocytes, 21 which secrete growth factors and proteases important for tissue remodeling. 22, 61 Third, they could work by upregulating plasminogen activator expression, which increases local fibrinolysis. 62 Treatment with the PHD inhibitor L-mimosine resulted in an approximately 2-fold increase in HIF1␣ expression in the thrombus. This reflects the increase in HIF1␣ seen in rat medulla following a similar treatment. 30 L-Mimosine treatment led to a 2-to 3-fold increase in vein recanalization and thrombus neovascularization, which is also comparable to the increase in microvessel density following a similar treatment in a rat sponge model of angiogenesis. 29 L-Mimosine treatment was unlikely to have affected thrombus formation, as it was administered 5 hours after stenosis of the IVC, and fully occlusive thrombi form within 4 hours in this model. 34 The similar thrombus weights of 24-hour-old thrombi obtained from mice treated with L-mimosine and vehicle controls provides further evidence that this treatment did not affect thrombogenesis.
Analysis of the effects of L-mimosine on thrombus resolution and vein recanalization was carried out at 2 time points: day 7, when thrombus organization is first readily visible (this or a similar time point have been used previously), 10, 12, 14, 15, 23, 24, 63 and day 10, when thrombus organization is well under way in this model. 33 By day 14, thrombus resolution is highly advanced, with only small thrombi visible within the IVC. 33 L-Mimosine treatment resulted in 21% recanalization at day 10 (compared with 8% seen at day 7). The difference in recanalization between treatment groups and respective controls was greater at day 10 (12%) than at day 7 (4%), suggesting that continuous L-mimosine treatment accelerated recanalization. Although assessment at a later time point (eg, day 16) may have revealed a reduction in time to complete resolution, comparison between treatments would probably have proved less reliable, as natural resolution in this model accelerates rapidly after 7 to 10 days, 33 resulting in a small and highly variable volume of remaining thrombus.
Adenovirus construct-mediated upregulation of VEGF increased IVC recanalization 3-fold and reduced thrombus size by half. 24 In this study, there was a more modest effect, with L-mimosine treatment doubling IVC recanalization and reducing thrombus size by one-third. L-Mimosine is known to inhibit other members of the 2-oxoglutarate-dependent dioxygenases, 28 including collagen hydroxylase, which regulates collagen synthesis. 64 This action would be expected to inhibit resolution, as collagen synthesis is an important component of the organization process. 63 These opposing actions of L-mimosine may account for some of the differences in the efficacy of the treatments between this and previous studies. The relatively short half-life of L-mimosine (approximately 5 hours in the rat 65 ) compared with the relatively long expression of a viral construct that continually produces VEGF for the duration of the experiment could also account for the lesser effect of L-mimosine on thrombus resolution and IVC recanalization. In this context, it is also important to note that the amount of L-mimosine that can be injected per day is limited by the solubility of the compound and the maximum permissible volume that can be injected.
VEGF levels in the thrombus induced by L-mimosine treatment were also 20-fold lower than those caused by treatment with the adenoviral VEGF construct 24 (20 versus 400 pg/mg, respectively), but L-mimosine still resulted in a 2-fold increase in IVC recanalization compared with the 3-fold increase induced by the adenoviral VEGF construct. 24 This might be explained by the increased expression of 13 other HIF1-mediated angiogenic factors in the thrombus of L-mimosine-treated mice compared with controls. All of these factors could contribute to thrombus resolution. Angiopoietin 1 activates the Tie2 receptor and mediates endothelial cell sprouting and formation of new vascular networks. 66 Endoglin is a marker of neovascular endothelium, 39 and endothelin 1 contributes to vascular remodeling by stimulating the growth and proliferation of vascular smooth muscle cells. 67 IGFBP1 modulates the effects of IGF1 and IGF2, which have important roles in vessel growth. 68 Leptin targets the vascular endothelium and induces neovascularization in vivo. 69 MCP1 levels increase in the thrombus as it resolves, and increasing the amount of MCP1 in the thrombus enhances thrombus organization and resolution. 10 MMP9 has been found in abundance in the resolving thrombus 63 and could facilitate thrombus canalization by degrading its extracellular matrix to facilitate the migration of endothelial cells. 70 Net extracellular matrix turnover is also affected by the level of the MMP inhibitor TIMP1. 71 The higher levels of TIMP seen in this study may reflect the increased production of MMP9, as this inhibitor is expressed to prevent MMP overactivity under physiological conditions. 71,72 PDGF-B can induce VEGF expression 73 and activate the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways, which stimulate HIF1␣ synthesis. 74 PLGF may promote thrombus recanalization by recruiting monocytes, mobilizing progenitor cells from the bone marrow, and affecting endothelial cells directly via VEGFR1, 75 which was also upregulated following L-mimosine treatment. SDF1 expression in ischemic tissue is directly proportional to reduced pO 2 . 46 HIF1-mediated SDF1 expression increases the migration and adhesion of circulating progenitor cells to ischemic tissue. 46 It is possible that HIF1-mediated expression of SDF1 increases bone marrow-derived progenitor cell recruitment to the resolving thrombus. 7 Under homeostatic conditions, SDF1 is also responsible for recruitment and homing of neutrophils, 76, 77 which infiltrate the thrombus during the early stages of resolution. 8, 12 These data suggest that the expression of other HIF1-mediated angiogenic cytokines and receptors (in addition to VEGF and VEGFR1) were induced by L-mimosine and may have helped to accelerate vein recanalization. This leads us to speculate that stimulating HIF1␣ in a more concerted way (eg, with a viral construct expressing stabilized HIF1␣ 38 ) could have an even greater impact on thrombus resolution and vein recanalization.
We provide data for the efficacy of L-mimosine in promoting thrombus resolution and IVC recanalization through HIF1-mediated induction of angiogenic factors. It is possible, however, that L-mimosine stimulated this process through pathways independent of HIF1␣, for example by stabilization of HIF2␣. 28 The importance of thrombus neovascularization in vein recanalization is also uncertain. Although it is likely that thrombus retraction has the greatest effect on vein recanalization (in terms of luminal cross-sectional area available for restoration of blood flow), this process may involve the coalescence of neovascular channels that form at the thrombus edge. The relative importance of each process remains to be defined.
L-Mimosine treatment led to increased numbers of inflammatory cells (neutrophils and macrophages) in the vein wall at day 7 but not in thrombi at this time point. It is possible that HIF1-mediated expression of cytokines and growth factors (such as endothelin 1 or others not measured in this study) could be responsible for the recruitment of these cells into the vein wall. 31 Treatment with L-mimosine for 10 days appeared to accelerate IVC recanalization and thrombus resolution, and this was associated with an increase of Ϸ50% in macrophage numbers in both the IVC and the thrombus. Macrophages are capable of generating a plethora of growth, chemotactic, and proteolytic agents that regulate tissue remodeling in wound healing and thrombosis, and ablating these cells has an impact on these processes. 8, 13, 15, 33, 39, 78, 79 There was also a small but significant increase in the numbers of neutrophils present in the thrombus and vein wall of L-mimosine-treated mice compared with controls at day 10. This was unexpected, as these cells are associated with the early thrombus, and their numbers reduce with time during natural resolution. 32, 80 Neutropenia retards thrombus resolution, 56 however, and it is possible that L-mimosine exerted some of its effects on this process by stimulating recruitment of neutrophils and preventing their apoptosis. 81, 82 Thrombus organization and recanalization appears to be driven through an "outside-in" process, 8 with inflammatory cells entering the thrombus via the vein wall. 8, 13, 15, 32, 33, 56 Relative hypoxia in the thrombus could provide a directional stimulus for the growth of microvessels from the vein wall into the thrombus, which, together with thrombus retraction, leads to vein recanalization and blood flow restoration. A better insight into the expression of transcription factors such as HIF1 and their target genes will lead to a greater understanding of the mechanisms responsible for natural thrombus resolution and vein recanalization. This could direct the development of novel treatments that enhance these processes and reduce the incidence of post-thrombotic complications.
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